Protocol for the development of a core outcome set and reporting guidelines for locoregional treatment in neoadjuvant systemic breast cancer treatment trials: the PRECEDENT project

Author:

Potter ShelleyORCID,Avery KerryORCID,Ahmed Rosina,de Boniface Jana,Chatterjee Sanjoy,Dodwell David,Dubsky Peter,Iwata Hiroji,Jiang Michael,Lee Han-Byoel,MacKenzie Mairead,Poulakaki Fiorita,Richardson Andrea L,Sepulveda Karla,Spillane Andrew,Thompson Alastair M,Werutsky Gustavo,Wright Jean L,Zdenkowski Nicholas,Cowan Katherine,McIntosh StuartORCID

Abstract

IntroductionNeoadjuvant systemic anticancer therapy (neoSACT) is increasingly used in the treatment of early breast cancer. Response to therapy is prognostic and allows locoregional and adjuvant systemic treatments to be tailored to minimise morbidity and optimise oncological outcomes and quality of life. Accurate information about locoregional treatments following neoSACT is vital to allow the translation of downstaging benefits into practice and facilitate meaningful interpretation of oncological outcomes, particularly locoregional recurrence. Reporting of locoregional treatments in neoSACT studies, however, is currently poor. The development of a core outcome set (COS) and reporting guidelines is one strategy by which this may be improved.Methods and analysisA COS for reporting locoregional treatment (surgery and radiotherapy) in neoSACT trials will be developed in accordance with Core Outcome Measures in Effectiveness Trials (COMET) and Core Outcome Set-Standards for Development guidelines. Reporting guidance will be developed concurrently.The project will have three phases: (1) generation of a long list of relevant outcome domains and reporting items from a systematic review of published neoSACT studies and interviews with key stakeholders. Identified items and domains will be categorised and formatted into Delphi consensus questionnaire items. (2) At least two rounds of an international online Delphi survey in which at least 250 key stakeholders (surgeons/oncologists/radiologists/pathologists/trialists/methodologists) will score the importance of reporting each outcome. (3) A consensus meeting with key stakeholders to discuss and agree the final COS and reporting guidance.Ethics and disseminationEthical approval for the consensus process will be obtained from the Queen’s University Belfast Faculty Ethics Committee. The COS/reporting guidelines will be presented at international meetings and published in peer-reviewed journals. Dissemination materials will be produced in collaboration with our steering group and patient advocates so the results can be shared widely.RegistrationThe study has been prospectively registered on the COMET website (https://www.comet-initiative.org/Studies/Details/2854).

Funder

Association of Breast Surgery of Great Britain and Ireland

Publisher

BMJ

Reference21 articles.

1. Bhattacharya I , Coles CE , Doughty J , et al . Neoadjuvant chemotherapy: multidisciplinary guidance. 2023. Available: https://associationofbreastsurgery.org.uk/media/515633/neaoadjuvant-chemotherapy-manual-v1.pdf

2. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

3. NCCN guidelines(R) insights: breast cancer, version 4.2023;Gradishar;J Natl Compr Canc Netw,2023

4. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

5. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3